Lasne Dominique, Bauters Anne, Le Querrec Agnès, Bourdin Carole, Voisin Sophie
Laboratoire d'hématologie, Hôpital Necker, Paris, France.
Laboratoire d'hématologie A, Hôpital cardiologique, Lille, France.
Ann Biol Clin (Paris). 2015 Mar-Apr;73(2):225-54. doi: 10.1684/abc.2015.1035.
Point of care testing (POCT) must comply with regulatory requirements according to standard EN ISO 22870, which identify biologists as responsible for POCT. Activated clotting time (ACT) is mandatory to monitor on whole blood, anticoagulation achieved by unfractionated heparin during cardiopulmonary bypass (CPB) or cardiac catheterization. This test has no equivalent in the laboratory. With the aim to help the multidisciplinary groups for POCT supervision when they have to analyse the wish of medical departments to use ACT and to help the biologists to be in accordance with the standard, we present the guidelines of the GEHT (Groupe d'étude d'hémostase et thrombose) subcommittee "CEC et Biologie délocalisée" for the certification of ACT. These guidelines are based on the SFBC guidelines for the certification of POCT and on the analysis of the literature to ascertain the justification of clinical need and assess the analytical performance of main analyzers used in France, as well as on a survey conducted with French and Belgian biologists.
即时检验(POCT)必须符合标准EN ISO 22870的监管要求,该标准确定生物学家为POCT的负责人。活化凝血时间(ACT)对于监测全血是强制性的,在体外循环(CPB)或心导管插入术中通过普通肝素实现抗凝时需要监测ACT。该检测在实验室中没有等效检测方法。为了在多学科小组必须分析医疗部门使用ACT的意愿时帮助其进行POCT监督,并帮助生物学家符合标准,我们介绍了GEHT(止血与血栓形成研究小组)“CEC与非本地化生物学”小组委员会关于ACT认证的指南。这些指南基于SFBC的POCT认证指南,并通过文献分析来确定临床需求的合理性,评估法国使用的主要分析仪的分析性能,以及基于对法国和比利时生物学家进行的一项调查。